Servier is actively conducting Phase 1/2 clinical trials for BDTX's RAF inhibitor, 'S241656'.
Phase 1/2 Clinical Trial of Novel RAF Inhibitor S241656 Progressing Smoothly
Servier, a French multinational pharmaceutical company, is leading the development of the innovative drug S241656 (formerly known as BDTX-4933), and its Phase 1/2 clinical trial (NCT05786924) is now in full swing globally. This trial aims to comprehensively evaluate the safety, pharmacokinetic properties, and preliminary efficacy of S241656 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) and gastrointestinal (GI) cancers, all of whom have genetic mutations in key RAS/MAPK signaling pathways involved in cancer cell proliferation and survival, including KRAS, HRAS, NRAS, BRAF, and CRAF (RAF1). Given the increasing clinical demand for precision oncology drugs that target solid tumors with the same oncogenic mutations, regardless of specific cancer type, this clinical trial is garnering significant attention from both the academic and market communities.
Differentiation through Brain Metastasis Inhibition and Overcoming Paradoxical MAPK Activation
S241656 is a next-generation, oral targeted anticancer drug that broadly inhibits the active conformation of various RAF proteins, which are crucial for the survival of tumor cells. Notably, it is designed to circumvent the paradoxical activation of the MAPK pathway, a common adverse effect associated with first-generation RAF inhibitors, thereby enhancing treatment safety. Furthermore, S241656 exhibits excellent blood-brain barrier (BBB) penetration, allowing it to target brain metastasis lesions, which are frequently observed in patients with NSCLC and GI cancers, providing a significant advantage over existing therapies.
Servier's Strategic Acquisition and Deal Structure to Enhance Asset Value
This promising pipeline was originally being developed by Black Diamond Therapeutics (BDTX), a Nasdaq-listed company. However, due to the company's financial situation and a strategic focus on core assets, development was temporarily halted last year. Servier recognized the potential of this pipeline and, in March 2025, entered into a global exclusive license agreement for a total of $780 million, fully acquiring the development rights. The $70 million upfront payment and the potential for $710 million in future milestone payments reflect the significant value and commercial expectations associated with this asset.
Synergy with Day One Acquisition and MAPK Pipeline
In April 2026, Servier acquired Day One Biopharmaceuticals, the developer of tovorafenib, which was approved for the treatment of pediatric low-grade glioma (pLGG), for $2.5 billion, significantly boosting its oncology business. This acquisition, along with the strategic acquisition of BDTX-4933, is part of Servier's consistent strategy to strengthen its portfolio and establish a leading position in the MAPK signaling pathway control market. With the global precision oncology market expected to grow by 11.3% annually, reaching approximately $338.8 billion by 2035, Servier's aggressive infrastructure integration and entry into late-stage clinical trials will drive the company's future value.
Servier's Phase 1/2 clinical trial of S241656 targets the highly unmet need in KRAS/BRAF-mutated solid tumors and will demonstrate strong market competitiveness in the global precision oncology market, which is growing at 11.3% annually and is expected to reach $338.8 billion by 2035. In particular, in conjunction with the $2.5 billion acquisition of Day One Biopharmaceuticals completed in April 2026, it creates research synergies with the approved drug tovorafenib, thereby solidifying its integrated leadership in the MAPK pathway pipeline. In the short term, securing safety data in Phase 1 and establishing optimal dosage will be key milestones in determining whether Black Diamond Therapeutics (BDTX) will receive the $710 million in milestone payments. In the medium to long term, a key point to watch will be whether S241656, which has the ability to control brain metastases, can demonstrate clinical superiority over other competing pipelines, such as Erasca's naporafenib, which is currently facing development challenges and seeking partnerships. The success of this clinical trial and deal will be a major milestone for medical researchers seeking to diversify precision solid tumor treatment options and for biotech investors seeking to improve asset efficiency.
Source: ClinicalTrials.gov (api_ct)